Aclaris therapeutics and pediatrix therapeutics announce license agreement for ati-1777 in greater china

Wayne, pa. and shanghai, china, nov. 29, 2022 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and pediatrix therapeutics, inc. (pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. under the license agreement, aclaris has granted pediatrix the exclusive rights to develop, manufacture and commercialize ati-1777, aclaris' investigational “soft” janus kinase (jak) 1/3 inhibitor, for any disease, including atopic dermatitis, in greater china (mainland china, hong kong, macau and taiwan). aclaris will retain the rights to develop, manufacture and commercialize ati-1777 in the rest of the world.
ACRS Ratings Summary
ACRS Quant Ranking